Objectives: The Gleason score (GS) is the primary classification of clinical risk in prostate cancer (PCa). Here, we estimated the factors predictive of accordance of local and central pathologist-dependent GS and clinical risk classification in an increased number of cases. Methods: Between January 2009 and December 2013, 388 patients were diagnosed with PCa by 80 independent pathologists from local communities and were referred to our hospital. Validation of the GS with needle-core biopsy specimens was carried out by a single central pathologist, and clinical risk, according to the D'Amico risk classification, was determined. Discrepancies between the GS and risk classification, based on the GS estimated by the local or central pathologist, were reviewed, and predictive factors for accordance of clinical risk classification were estimated. Results: When pathological results were compared, 59.5% of cases were given concordant GSs by local and central pathologists. A significant discrepancy existed in the classification of intermediate risk (p < 0.0001). Multivariate analysis indicated that local pathologist-dependent GS7, lower prostate-specific antigen (≤10 ng/ml), and lower T stage (T1 or T2a) were significant predictive factors for discordance with the central pathologist-dependent risk classification. Conclusion: Review of bioptic GSs by central pathologists affected discrepancies in risk classification in patients with PCa.

Keywords:
Risk classification, Gleason score, Prostate cancer, Pathological grading
1.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-1092.
2.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
3.
Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-128.
4.
Barqawi AB, Turcanu R, Gamito EJ, Lucia SM, O'Donnell CI, Crawford ED, La Rosa DD, La Rosa FG: The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer. Int J Clin Exp Pathol 2011;4:468-475.
5.
Sooriakumaran P, Lovell DP, Henderson A, Denham P, Langley SE, Laing RW: Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer. Clin Oncol (R Coll Radiol) 2005;17:655-658.
6.
Nguyen PL, Schultz D, Renshaw AA, Vollmer RT, Welch WR, Cote K, D'Amico AV: The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol 2004;22:295-299.
7.
Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI: Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21:566-576.
8.
Köksal IT, Ozcan F, Kadioglu TC, Esen T, Kiliçaslan I, Tunç M: Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens. Eur Urol 2000;37:670-674.
9.
Fukagai T, Namiki T, Namiki H, Carlile RG, Shimada M, Yoshida H: Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens. Pathol Int 2001;51:364-370.
10.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee: The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-1242.
11.
Dong F, Yang P, Wang C, Wu S, Xiao Y, McDougal WS, Young RH, Wu CL: Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 2013;37:1855-1861.
12.
Dong F, Wang C, Farris AB, Wu S, Lee H, Olumi AF, McDougal WS, Young RH, Wu CL: Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol 2012;36:838-843.
13.
Lavery HJ, Droller MJ: Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? J Urol 2012;188:1667-1675.
14.
Pierorazio PM, Walsh PC, Partin AW, Epstein JI: Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013;111:753-760.
15.
Mikami Y, Manabe T, Epstein JI, Shiraishi T, Furusato M, Tsuzuki T, Matsuno Y, Sasano H: Accuracy of Gleason grading by practicing pathologists and the impact of education on improving agreement. Hum Pathol 2003;34:658-665.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.